Old Web
English
Sign In
Acemap
>
authorDetail
>
E Muratti
E Muratti
Bristol-Myers Squibb
Abatacept
Physical therapy
Medicine
Adalimumab
Internal medicine
3
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
SAT0195 Rituximab shows better sustainability than tnf inhibitors when used following initial biologic dmard failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the rhumadata® clinical database and registry
2017
Annals of the Rheumatic Diseases
Denis Choquette
Louis Bessette
Evo Alemao
Boulos Haraoui
Frédéric Massicotte
M Mtibaa
E Muratti
J.-P. Pelletier
Roelien Postema
J-P Raynauld
M.-A. Rémillard
D. Sauvageau
A Turcotte
Έ. Villeneuve
L. Coupal
Show All
Source
Cite
Save
Citations (0)
FRI0230 Retention rates of tnf inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the rhumadata® registry
2017
Annals of the Rheumatic Diseases
D. Choquette
Louis Bessette
E. Alemao
Boulos Haraoui
Frédéric Massicotte
Mondher Mtibaa
E Muratti
J.-P. Pelletier
R. Postema
J.P. Raynauld
M.-A. Rémillard
D. Sauvageau
A Turcotte
Έ. Villeneuve
L. Coupal
Show All
Source
Cite
Save
Citations (1)
THU0089 M-DAS28, DAS28 (CRP) and RAPID3 scores at baseline are good predictors of radiographic disease progression at 1 and 2 years: data from the ample trial
2017
Annals of the Rheumatic Diseases
E. Keystone
H Ahmad
Yusuf Yazici
E Muratti
J Ye
Martin J. Bergman
Show All
Source
Cite
Save
Citations (0)
1